

Kathryn J Fowler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2006499/publications.pdf>

Version: 2024-02-01

193
papers

7,704
citations

66250

44
h-index

73587

79
g-index

200
all docs

200
docs citations

200
times ranked

10107
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular Carcinoma Staging: Differences Between Radiologic and Pathologic Systems and Relevance to Patient Selection and Outcomes in Liver Transplantation. American Journal of Roentgenology, 2022, 218, 77-86.	1.0	9
2	PET/MR imaging in gynecologic cancer: tips for differentiating normal gynecologic anatomy and benign pathology versus cancer. Abdominal Radiology, 2022, 47, 3189-3204.	1.0	6
3	Automated Liver Segmentation for Quantitative MRI Analysis. Radiology, 2022, 302, 355-356.	3.6	2
4	Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease. European Radiology, 2022, 32, 2457-2469.	2.3	19
5	Automated CNN-Based Analysis Versus Manual Analysis for MR Elastography in Nonalcoholic Fatty Liver Disease: Intermethod Agreement and Fibrosis Stage Discriminative Performance. American Journal of Roentgenology, 2022, 219, 224-232.	1.0	6
6	Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. Nature Medicine, 2022, 28, 430-432.	15.2	33
7	Impact of Pretransplantation CT on Liver Donation in Potential Deceased Organ Donors. Journal of the American College of Surgeons, 2022, 234, 166-175.	0.2	3
8	Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. Alimentary Pharmacology and Therapeutics, 2022, 55, 820-827.	1.9	30
9	LR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR-TR Lesions. Digestive Diseases and Sciences, 2022, , 1.	1.1	1
10	Eliciting Patient Preferences for Hepatocellular Carcinoma Screening: A Choice-Based Conjoint Analysis. Journal of the American College of Radiology, 2022, 19, 502-512.	0.9	3
11	Liver imaging: it is time to adopt standardized terminology. European Radiology, 2022, 32, 6291-6301.	2.3	13
12	Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD. Radiology, 2022, , 211131.	3.6	12
13	ACR Appropriateness Criteria® Staging of Colorectal Cancer: 2021 Update. Journal of the American College of Radiology, 2022, 19, S208-S222.	0.9	6
14	Point-of-care magnetic resonance technology to measure liver fat: Phantom and first human pilot study. Magnetic Resonance in Medicine, 2022, 88, 1794-1805.	1.9	6
15	Gender and racial diversity among plenary session speakers at the Society of Abdominal Radiology Annual Meetings: a five-year assessment. Abdominal Radiology, 2022, 47, 2545-2551.	1.0	6
16	Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 2274-2283.e5.	2.4	95
17	Imaging diagnosis of hepatocellular carcinoma: LI-RADS. Chinese Clinical Oncology, 2021, 10, 3-3.	0.4	16
18	Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19mm) HCC on extracellular contrast-enhanced MRI. Abdominal Radiology, 2021, 46, 1530-1542.	1.0	11

#	ARTICLE	IF	CITATIONS
19	Online Liver Imaging Course; Pivoting to Transform Radiology Education During the SARS-CoV-2 Pandemic. <i>Academic Radiology</i> , 2021, 28, 119-127.	1.3	21
20	LI-RADS and transplantation: challenges and controversies. <i>Abdominal Radiology</i> , 2021, 46, 29-42.	1.0	8
21	Improved survival following transarterial radioembolization of infiltrative-appearance hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2021, 46, 1958-1966.	1.0	6
22	Repeatability and accuracy of various region-of-interest sampling strategies for hepatic MRI proton density fat fraction quantification. <i>Abdominal Radiology</i> , 2021, 46, 3105-3116.	1.0	5
23	Liver Imaging and Data System (LI-RADS) Version 2018 and Other Imaging Features in Intrahepatic Cholangiocarcinoma in Chinese Adults with vs. without Chronic Hepatitis B Viral Infection. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-10.	0.8	3
24	Abbreviated Magnetic Resonance Imaging for HCC Surveillance. <i>Clinical Liver Disease</i> , 2021, 17, 133-138.	1.0	6
25	Magnetic resonance elastography biomarkers for detection of histologic alterations in nonalcoholic fatty liver disease in the absence of fibrosis. <i>European Radiology</i> , 2021, 31, 8408-8419.	2.3	6
26	Multi-arterial phase MRI depicts inconsistent arterial phase hyperenhancement (APHE) subtypes in liver observations of patients at risk for hepatocellular carcinoma. <i>European Radiology</i> , 2021, 31, 7594-7604.	2.3	4
27	Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 513-527.	1.8	16
28	Accurate Prostate Volumes from Manual Calculationsâ€”A Comparison of PI-RADS v2 and v2.1 Measurement Techniques. <i>Academic Radiology</i> , 2021, 28, 1557-1558.	1.3	1
29	Quantitative magnetic resonance imaging for chronic liver disease. <i>British Journal of Radiology</i> , 2021, 94, 20201377.	1.0	12
30	HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy. <i>Abdominal Radiology</i> , 2021, 46, 3686-3697.	1.0	1
31	MR Imaging of Diffuse Liver Disease. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2021, 29, 347-358.	0.6	0
32	Magnetic Resonance Imaging of Nonhepatocellular Malignancies in Chronic Liver Disease. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2021, 29, 404-418.	0.6	2
33	How to Use LI-RADS to Report Liver CT and MRI Observations. <i>Radiographics</i> , 2021, 41, 1352-1367.	1.4	13
34	Imaging Features at the Periphery: Hemodynamics, Pathophysiology, and Effect on LI-RADS Categorization. <i>Radiographics</i> , 2021, 41, 1657-1675.	1.4	7
35	Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma. <i>Radiographics</i> , 2021, 41, 1611-1631.	1.4	32
36	CNN color-coded difference maps accurately display longitudinal changes in liver MRI-PDFF. <i>European Radiology</i> , 2021, 31, 5041-5049.	2.3	1

#	ARTICLE	IF	CITATIONS
37	Targetoid appearance on T2-weighted imaging and signs of tumor vascular involvement: diagnostic value for differentiating HCC from other primary liver carcinomas. <i>European Radiology</i> , 2021, 31, 6868-6878.	2.3	9
38	Accuracy and Variability of Prostate Multiparametric Magnetic Resonance Imaging Interpretation Using the Prostate Imaging Reporting and Data System: A Blinded Comparison of Radiologists. <i>European Urology Focus</i> , 2020, 6, 267-272.	1.6	23
39	Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastography. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 25-42.	1.9	53
40	Hepatocellular adenomas: Understanding the pathomolecular lexicon, MRI features, terminology, and pitfalls to inform a standardized approach. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1630-1640.	1.9	20
41	Deep convolutional neural network applied to the liver imaging reporting and data system (LI-RADS) version 2014 category classification: a pilot study. <i>Abdominal Radiology</i> , 2020, 45, 24-35.	1.0	28
42	Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors. <i>European Radiology</i> , 2020, 30, 996-1007.	2.3	14
43	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1917-1925.	0.9	11
44	Assessing Radiology Research on Artificial Intelligence: A Brief Guide for Authors, Reviewers, and Readers" From the <i>Radiology</i> Editorial Board. <i>Radiology</i> , 2020, 294, 487-489.	3.6	229
45	Imaging Diagnosis of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 623-636.	1.0	7
46	Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. <i>Radiographics</i> , 2020, 40, 1916-1931.	1.4	43
47	The relationship between liver triglyceride composition and proton density fat fraction as assessed by 1 H MRS. <i>NMR in Biomedicine</i> , 2020, 33, e4286.	1.6	9
48	Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. <i>European Radiology</i> , 2020, 30, 6003-6013.	2.3	43
49	Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. <i>Hepatology</i> , 2020, 72, 1219-1229.	3.6	79
50	Editorial on "Head-to-Head Comparison of PI-RADS Version 2 and 2.1 in Transition Zone Lesions for Detection of Prostate Cancer": <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 587-588.	1.9	1
51	Examining LI-RADS recommendations: should observation size only be measured on non-arterial phases?. <i>Abdominal Radiology</i> , 2020, 45, 3144-3154.	1.0	2
52	Prospective comparison of longitudinal change in hepatic proton density fat fraction (PDFF) estimated by magnitude-based MRI (MRI-M) and complex-based MRI (MRI-C). <i>European Radiology</i> , 2020, 30, 5120-5129.	2.3	2
53	Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection. <i>Bosnian Journal of Basic Medical Sciences</i> , 2020, 20, 401-410.	0.6	10
54	Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI. <i>Hepatoma Research</i> , 2020, 2020, .	0.6	10

#	ARTICLE	IF	CITATIONS
55	Common pitfalls when using the Liver Imaging Reporting and Data System (LI-RADS): lessons learned from a multi-year experience. <i>Abdominal Radiology</i> , 2019, 44, 43-53.	1.0	10
56	Novel Imaging Approaches in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 248-260.	0.9	13
57	Reply to "Letter to the editor". <i>Abdominal Radiology</i> , 2019, 44, 3209-3209.	1.0	0
58	Liver Imaging Reporting and Data System Version 2018: Impact on Categorization and Hepatocellular Carcinoma Staging. <i>Liver Transplantation</i> , 2019, 25, 1488-1502.	1.3	20
59	Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria. <i>Hpb</i> , 2019, 21, 1697-1706.	0.1	16
60	Repeatability of Quantitative Brown Adipose Tissue Imaging Metrics on Positron Emission Tomography with 18F-Fluorodeoxyglucose in Humans. <i>Cell Metabolism</i> , 2019, 30, 212-224.e4.	7.2	21
61	Crohn's Disease Is Associated With an Increased Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study Using Magnetic Resonance Proton Density Fat Fraction Mapping. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2816-2818.	2.4	19
62	CT/MR LI-RADS 2018: clinical implications and management recommendations. <i>Abdominal Radiology</i> , 2019, 44, 1306-1322.	1.0	28
63	User and system pitfalls in liver imaging with LI-RADS. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1673-1686.	1.9	18
64	Magnetic resonance enterography features of small bowel Crohn's disease activity: an inter-rater reliability study of small bowel active inflammation in clinical practice setting. <i>British Journal of Radiology</i> , 2019, 92, 20180930.	1.0	10
65	Diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) v2017 in predicting malignant liver lesions in pediatric patients: a preliminary study. <i>Pediatric Radiology</i> , 2019, 49, 746-758.	1.1	13
66	ACR Appropriateness Criteria® Left Lower Quadrant Pain-Suspected Diverticulitis. <i>Journal of the American College of Radiology</i> , 2019, 16, S141-S149.	0.9	26
67	Is It Time to Expand the Definition of Washout Appearance in LI-RADS?. <i>Radiology</i> , 2019, 291, 658-659.	3.6	14
68	A diagnosis reconsidered: the symptomatic gallbladder remnant. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2019, 26, 137-143.	1.4	6
69	An update for LI-RADS: Version 2018. Why so soon after version 2017?. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1990-1991.	1.9	19
70	Living Donor Liver Transplantation: Overview, Imaging Technique, and Diagnostic Considerations. <i>American Journal of Roentgenology</i> , 2019, 213, 54-64.	1.0	10
71	Living Donor Liver Transplantation: Preoperative Planning and Postoperative Complications. <i>American Journal of Roentgenology</i> , 2019, 213, 65-76.	1.0	12
72	LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 49-69.	1.8	93

#	ARTICLE	IF	CITATIONS
73	Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018. <i>Abdominal Radiology</i> , 2019, 44, 2116-2132.	1.0	52
74	Pilot study on longitudinal change in pancreatic proton density fat fraction during a weight loss surgery program in adults with obesity. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1092-1102.	1.9	16
75	Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy: A Systematic Review. <i>Gastroenterology</i> , 2019, 156, 976-986.	0.6	221
76	Measurement Repeatability of ¹⁸ F-FDG PET/CT Versus ¹⁸ F-FDG PET/MRI in Solid Tumors of the Pelvis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1080-1086.	2.8	23
77	Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1228-1238.	2.4	41
78	ACR Appropriateness Criteria® Palpable Abdominal Mass-Suspected Neoplasm. <i>Journal of the American College of Radiology</i> , 2019, 16, S384-S391.	0.9	8
79	The Role of Preoperative Dynamic Contrast-enhanced 3.0-T MR Imaging in Predicting Early Recurrence in Patients With Early-Stage Hepatocellular Carcinomas After Curative Resection. <i>Frontiers in Oncology</i> , 2019, 9, 1336.	1.3	22
80	Magnetic resonance imaging of the placenta and gravid uterus: a pictorial essay. <i>Abdominal Radiology</i> , 2019, 44, 669-684.	1.0	8
81	Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS). <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 1236-1252.	1.9	23
82	Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 1456-1466.	1.9	28
83	Hepatic steatosis and reduction in steatosis following bariatric weight loss surgery differs between segments and lobes. <i>European Radiology</i> , 2019, 29, 2474-2480.	2.3	11
84	Quantitative MRI of Diffuse Liver Disease: Current Applications and Future Directions. <i>Radiology</i> , 2019, 290, 23-30.	3.6	26
85	Pitfalls in liver MRI: Technical approach to avoiding misdiagnosis and improving image quality. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 41-58.	1.9	13
86	Quantitative multiparametric MR analysis of small renal lesions: correlation with surgical pathology. <i>Abdominal Radiology</i> , 2018, 43, 3390-3399.	1.0	10
87	Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatrics</i> , 2018, 198, 76-83.e2.	0.9	24
88	LI-RADS 2017: An update. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1459-1474.	1.9	34
89	Assessment and optimization of liver volume before major hepatic resection: Current guidelines and a narrative review. <i>International Journal of Surgery</i> , 2018, 52, 74-81.	1.1	75
90	CHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. <i>Hepatology</i> , 2018, 68, 113-126.	3.6	244

#	ARTICLE	IF	CITATIONS
91	PET/MRI for Gynecological Malignancies. , 2018, , 321-339.		0
92	Serum alpha-fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resection. Surgery, 2018, 163, 1002-1007.	1.0	14
93	CAPTURE: Consistently Acquired Projections for Tuned and Robust Estimation. Investigative Radiology, 2018, 53, 293-305.	3.5	12
94	Epidemiology of Hepatic Steatosis at a Tertiary Care Center. Academic Radiology, 2018, 25, 317-327.	1.3	9
95	Liver fat imaging—a clinical overview of ultrasound, CT, and MR imaging. British Journal of Radiology, 2018, 91, 20170959.	1.0	164
96	Letter to the editor response. Abdominal Radiology, 2018, 43, 239-239.	1.0	0
97	Evidence Supporting LI-RADS Major Features for CT- and MR Imaging–based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. Radiology, 2018, 286, 29-48.	3.6	230
98	In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2018, 16, 438-446.e1.	2.4	56
99	LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdominal Radiology, 2018, 43, 149-157.	1.0	82
100	LI-RADS and transplantation for hepatocellular carcinoma. Abdominal Radiology, 2018, 43, 193-202.	1.0	24
101	Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multireader Study. Radiology, 2018, 286, 173-185.	3.6	84
102	Technical report: gadoxetate-disodium-enhanced 2D R2* mapping: a novel approach for assessing bile ducts in living donors. Abdominal Radiology, 2018, 43, 1656-1660.	1.0	2
103	LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdominal Radiology, 2018, 43, 56-74.	1.0	58
104	Differentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014. Radiology, 2018, 286, 158-172.	3.6	100
105	Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdominal Radiology, 2018, 43, 218-230.	1.0	86
106	LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdominal Radiology, 2018, 43, 75-81.	1.0	55
107	Cirrhosis and LI-RADS. Abdominal Radiology, 2018, 43, 26-40.	1.0	12
108	Practical Considerations for Clinical PET/MR Imaging. PET Clinics, 2018, 13, 97-112.	1.5	8

#	ARTICLE	IF	CITATIONS
109	ACR Appropriateness Criteria® Right Lower Quadrant Pain-Suspected Appendicitis. Journal of the American College of Radiology, 2018, 15, S373-S387.	0.9	85
110	CT Assessment of Pancreatic Cancer: What Are the Gaps in Predicting Surgical Outcomes?. Radiology, 2018, 289, 719-720.	3.6	3
111	JOURNAL CLUB: Hepatopancreaticobiliary Imaging Second-Opinion Consultations: Is There Value in the Second Reading?. American Journal of Roentgenology, 2018, 211, 1264-1272.	1.0	14
112	Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology, 2018, 289, 816-830.	3.6	634
113	ACR Appropriateness Criteria® Acute Nonlocalized Abdominal Pain. Journal of the American College of Radiology, 2018, 15, S217-S231.	0.9	42
114	The Feasibility of Using Volumetric Phase-Contrast MR Imaging (4D Flow) to Assess for Transjugular Intrahepatic Portosystemic Shunt Dysfunction. Journal of Vascular and Interventional Radiology, 2018, 29, 1717-1724.	0.2	12
115	Hepatocellular carcinoma: Where are we in 2018?. Current Problems in Surgery, 2018, 55, 450-503.	0.6	2
116	Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer. EJNMMI Research, 2018, 8, 52.	1.1	11
117	Recommendation for terminology: Nodules without arterial phase hyperenhancement and with hepatobiliary phase hypointensity in chronic liver disease. Journal of Magnetic Resonance Imaging, 2018, 48, 1169-1171.	1.9	27
118	LI-RADS v2018: a Primer and Update for Clinicians. Current Hepatology Reports, 2018, 17, 425-433.	0.4	0
119	Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1193-1199.	2.3	40
120	White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI. Abdominal Radiology, 2018, 43, 2625-2642.	1.0	56
121	Cognitive Versus Software Fusion for MRI-targeted Biopsy: Experience Before and After Implementation of Fusion. Urology, 2018, 119, 115-120.	0.5	27
122	Improved Detection of Clinically Significant Prostate Cancer With Software-assisted Systematic Biopsy Using MR/US Fusion in Patients With Negative Prostate MRI. Urology, 2018, 120, 162-166.	0.5	4
123	Spectrum of Pitfalls, Pseudolesions, and Misdiagnoses in Noncirrhotic Liver. American Journal of Roentgenology, 2018, 211, 97-108.	1.0	8
124	PET/MRI for Gastrointestinal Imaging. Gastroenterology Clinics of North America, 2018, 47, 691-714.	1.0	5
125	ACR Appropriateness Criteria® Colorectal Cancer Screening. Journal of the American College of Radiology, 2018, 15, S56-S68.	0.9	23
126	Considerations in Imaging Among Emergency Department Patients With Inflammatory Bowel Disease. Annals of Emergency Medicine, 2017, 69, 587-599.	0.3	17

#	ARTICLE	IF	CITATIONS
127	Author Reply. <i>Urology</i> , 2017, 102, 196-197.	0.5	0
128	Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. <i>Hpb</i> , 2017, 19, 133-139.	0.1	54
129	Gadolinium-based contrast agents: A comprehensive risk assessment. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 338-353.	1.9	278
130	Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. <i>Journal of the American College of Surgeons</i> , 2017, 224, 610-621.	0.2	52
131	Practical Considerations for Clinical PET/MR Imaging. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2017, 25, 281-296.	0.6	5
132	Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation. <i>Journal of the American College of Surgeons</i> , 2017, 225, 28-40.	0.2	24
133	ACR Appropriateness Criteria® Pretreatment Staging of Colorectal Cancer. <i>Journal of the American College of Radiology</i> , 2017, 14, S234-S244.	0.9	66
134	Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2017, 153, 753-761.	0.6	209
135	Liver transplantation for hepatocellular carcinoma. <i>Current Opinion in Organ Transplantation</i> , 2017, 22, 128-134.	0.8	11
136	Magnetic resonance imaging of first trimester pregnancy: expected intrauterine contents in relation to gestational age. <i>Abdominal Radiology</i> , 2017, 42, 2334-2339.	1.0	3
137	Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. <i>Journal of Pediatrics</i> , 2017, 187, 141-146.e1.	0.9	91
138	MRI of suspected appendicitis during pregnancy: interradiologist agreement, indeterminate interpretation and the meaning of non-visualization of the appendix. <i>British Journal of Radiology</i> , 2017, 90, 20170383.	1.0	16
139	Liver Imaging for Colorectal Cancer Metastases. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 470-480.	1.0	3
140	Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 127-131.e2.	2.4	66
141	Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary?. <i>Urology</i> , 2017, 102, 190-197.	0.5	32
142	2017 Version of LI-RADS for CT and MR Imaging: An Update. <i>Radiographics</i> , 2017, 37, 1994-2017.	1.4	185
143	Liver Imaging Reporting and Data System: an expert consensus statement. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 29-39.	1.8	46
144	Prostate MRI: a national survey of Urologists' attitudes and perceptions. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2016, 42, 464-471.	0.7	16

#	ARTICLE	IF	CITATIONS
145	Clinical application of PET/MRI in oncology. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 265-276.	1.9	45
146	Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging. <i>Hpb</i> , 2016, 18, 296-303.	0.1	48
147	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 651-662.	5.1	557
148	Presence of Magnetic Resonance Imaging Suspicious Lesion Predicts Gleason 7 or Greater Prostate Cancer in Biopsy-Naive Patients. <i>Urology</i> , 2016, 88, 119-124.	0.5	19
149	PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 855-864.	0.9	58
150	Indeterminate Findings on Oncologic PET/CT: What Difference Does PET/MRI Make?. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 292-299.	0.6	9
151	Endovascular intervention for deep venous thrombosis in patients with inferior vena cava filters. <i>Vascular Medicine</i> , 2016, 21, 459-466.	0.8	6
152	Beyond Histologic Staging: Emerging Imaging Strategies in Colorectal Cancer with Special Focus on Magnetic Resonance Imaging. <i>Clinics in Colon and Rectal Surgery</i> , 2016, 29, 205-215.	0.5	5
153	The Emerging Role of PET/MR Imaging in Gynecologic Cancers. <i>PET Clinics</i> , 2016, 11, 425-440.	1.5	18
154	In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. <i>Gastroenterology</i> , 2016, 151, 1141-1154.e9.	0.6	100
155	Clinical application of PET/MRI in oncology. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, spcone-spcone.	1.9	0
156	Multimodality Imaging Approach towards Primary Aortic Sarcomas Arising after Endovascular Abdominal Aortic Aneurysm Repair: Case Series Report. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 940-947.	0.9	13
157	Imaging of the Patient with Thoracic Outlet Syndrome. <i>Radiographics</i> , 2016, 36, 984-1000.	1.4	81
158	Conspicuity of FDG-Avid Osseous Lesions on PET/MRI Versus PET/CT: a Quantitative and Visual Analysis. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 228-239.	0.6	5
159	Imaging Features of Biphenotypic Primary Liver Carcinoma (Hepatocholangiocarcinoma) and the Potential to Mimic Hepatocellular Carcinoma: LI-RADS Analysis of CT and MRI Features in 61 Cases. <i>American Journal of Roentgenology</i> , 2016, 207, 25-31.	1.0	96
160	New Approaches to Molecular Imaging of Multiple Myeloma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1-4.	2.8	39
161	PET/MRI:. <i>Academic Radiology</i> , 2016, 23, 220-236.	1.3	57
162	Imaging of Plasma Cell Dyscrasias with FDG-PET/MRI: A Single-Center Experience. <i>Blood</i> , 2016, 128, 5611-5611.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1468-1473.	2.3	9
164	Peripheral Restricted Diffusion. <i>Journal of Computer Assisted Tomography</i> , 2015, 39, 890-895.	0.5	3
165	Beyond Whole-Body Imaging. <i>Clinical Nuclear Medicine</i> , 2015, 40, e88-e95.	0.7	7
166	Imaging of tailgut cysts. <i>Abdominal Imaging</i> , 2015, 40, 2783-2795.	2.0	25
167	PET/MRI Evaluation of Gynecologic Malignancies and Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 293-303.	2.5	32
168	Magnetic resonance imagingâ€“targeted vs. conventional transrectal ultrasoundâ€“guided prostate biopsy: Single-institution, matched cohort comparison. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 109.e1-109.e6.	0.8	10
169	PET/MRI for the body imager: abdominal and pelvic oncologic applications. <i>Abdominal Imaging</i> , 2015, 40, 1387-1404.	2.0	23
170	ACR Appropriateness Criteria Crohn Disease. <i>Journal of the American College of Radiology</i> , 2015, 12, 1048-1057.e4.	0.9	39
171	Hot spleen: hypervascular lesions of the spleen. <i>Abdominal Imaging</i> , 2015, 40, 2796-2813.	2.0	18
172	Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 4130-4137.	0.7	29
173	Hepatobiliary agents and their role in LI-RADS. <i>Abdominal Imaging</i> , 2015, 40, 613-625.	2.0	105
174	MRI of the stomach: a pictorial review with a focus on oncological applications and gastric motility. <i>Abdominal Imaging</i> , 2015, 40, 907-930.	2.0	5
175	Imaging Approach to Hepatocellular Carcinoma, Cholangiocarcinoma, and Metastatic Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 19-40.	0.6	11
176	Prostate Magnetic Resonance Imaging: Challenges of Implementation. <i>Current Problems in Diagnostic Radiology</i> , 2015, 44, 26-37.	0.6	7
177	Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. <i>Abdominal Imaging</i> , 2014, 39, 310-322.	2.0	56
178	Magnetic resonance imaging of iatrogeny: understanding imaging artifacts related to medical devices. <i>Abdominal Imaging</i> , 2014, 39, 411-423.	2.0	6
179	Wholeâ€“body simultaneous positron emission tomography (PET)â€“MR: Optimization and adaptation of MRI sequences. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 259-268.	1.9	22
180	Emergency Thoracic Vascular Magnetic Resonance Imaging: Protocols and Clinical Considerations. <i>Seminars in Roentgenology</i> , 2014, 49, 157-168.	0.2	3

#	ARTICLE	IF	CITATIONS
181	Cervical Gross Tumor Volume Dose Predicts Local Control Using Magnetic Resonance Imaging/Diffusion-Weighted Imagingâ€”Guided High-Dose-Rate and Positron Emission Tomography/Computed Tomographyâ€”Guided Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 794-801.	0.4	52
182	ACR Appropriateness Criteria Colorectal Cancer Screening. <i>Journal of the American College of Radiology</i> , 2014, 11, 543-551.	0.9	31
183	Imaging of Trauma in the Pregnant Patient. <i>Radiographics</i> , 2014, 34, 748-763.	1.4	68
184	Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI. <i>Hepatic Oncology</i> , 2014, 1, 95-105.	4.2	0
185	Magnetic Resonance Enterography in the Evaluation of Crohnâ€™s Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2179-2188.	0.9	5
186	Current surgical treatment strategies for hepatocellular carcinoma in North America. <i>World Journal of Gastroenterology</i> , 2014, 20, 15007.	1.4	19
187	Combined Hepatocellular and Cholangiocarcinoma (Biphenotypic) Tumors: Imaging Features and Diagnostic Accuracy of Contrast-Enhanced CT and MRI. <i>American Journal of Roentgenology</i> , 2013, 201, 332-339.	1.0	173
188	Sensitivity of Endoscopic Ultrasound, Multidetector Computed Tomography, and Magnetic Resonance Cholangiopancreatography in the Diagnosis of Pancreas Divisum. <i>Pancreas</i> , 2013, 42, 436-441.	0.5	42
189	Validation of Organ Procurement and Transplant Network (OPTN)/United Network for Organ Sharing (UNOS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma. <i>Transplantation</i> , 2013, 95, 1506-1511.	0.5	28
190	Magnetic resonance imaging of focal liver lesions: Approach to imaging diagnosis. <i>Hepatology</i> , 2011, 54, 2227-2237.	3.6	90
191	Use of Microcalcification Descriptors in BI-RADS 4th Edition to Stratify Risk of Malignancy. <i>Radiology</i> , 2007, 242, 388-395.	3.6	168
192	Building successful coalitions for promoting advance care planning. <i>American Journal of Hospice and Palliative Medicine</i> , 2006, 23, 119-126.	0.8	11
193	Building successful coalitions to promote advance care planning. <i>American Journal of Hospice and Palliative Medicine</i> , 2005, 22, 437-441.	0.8	7